AbCellera Reports Q2 2026 Business Results
AbCellera reported Q2 revenue of $4.1 million, a significant decrease from $17.1 million in the prior year, while the net loss widened to $55.4 million from $34.7 million. Operational highlights overshadowed the financial decline, highlighted by new collaborations with Jazz Pharmaceuticals and Vertex Pharmaceuticals that bring in over $112 million in combined upfront payments and bolster total liquidity to $675 million.
Key figures
- Revenue
- $4.1 million
- Guidance
- ABCL635 top-line data expected in August 2026; ABCL575 top-line data expected in Q4 2026
- Net loss
- $55.4 million
- Jazz upfront
- $84 million
- Vertex upfront
- $28 million
- Total liquidity
- $675 million
- Partner programs
- 35
- Cash and securities
- $565 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.